Written by Arlene Weintraub
Immuno-oncology stole the spotlight again at this year’s annual meeting of the American Society of Clinical Oncology (ASCO). Recent data showed that Merck’s checkpoint inhibitor Keytruda cuts the risk of death significantly in newly diagnosed lung cancer patients and Bristol-Myers Squibb made a for Opdivo combos.
Earlier-stage I-O treatments were highlighted at the conference too, including a modified form of poliovirus originally developed at Duke University. The closely watched virus is now in clinical trials in glioblastoma, but preclinical results released at ASCO showed it may also help patients with hard-to-treat breast tumors. Read more.
Share this story
‹ More Featured Studies